People at high risk of lung cancer will soon be able to receive the first-ever experimental vaccine, 'LungVax', designed to prevent the disease, in a world-first clinical trial. The LungVax vaccine carries a series of genetic instructions which train the immune system to recognise tumour antigens on the surface of abnormal lung cells.
Researchers at the Kennedy Institute have provided the most comprehensive overview to date of how the distinctive segmented nucleus of neutrophils influences their function in health and disease.
Professor Tonia Vincent is part of an interdisciplinary team from Oxford University leading a major new initiative which aims to redefine human-based research models for greater understanding of disease and the acceleration of new medicines.
Researchers at the MRC Translational Immune Discovery Unit have identified how rare populations of abnormal cells drive the formation and persistence of fistulas - painful, tunnel-like tracts that develop in around 30% of people with Crohn\u2019s disease - paving the way for targeted treatments.
The Society for Immunotherapy of Cancer (SITC) has honoured Dr Ignacio (Nacho) Melero, Professor of Immunotherapy at NDM's Centre for Immuno-Oncology at Oxford, for his pioneering research transforming cancer treatment through immunotherapy.
Radcliff Department of Medicine scientists have achieved the most detailed view yet of how DNA folds and functions inside living cells, revealing the physical structures that control when and how genes are switched on.
Researchers from the Kennedy Institute are part of a UK-wide consortium that has been awarded a \u00a3644K BBSRC Network Grant to establish the Microbiome Innovation Network (Microbiome-Net).
Members of the Department of Oncology attended ESMO earlier this month to present their research, chair sessions, and network with collaborators from across Europe and beyond. Read the highlights from our department\u2019s contributions to ESMO 2025.
Three UK universities have been granted over \u00a31.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.
From 29 September to 1 October 2025, researchers from across the world gathered in Oxford for a unique conference and hackathon exploring how advances in artificial intelligence can deepen understanding of T-cell biology.
Teaming up with scientists and clinician-scientists at the University of Birmingham, and with 2025 Nobel Prize winner Professor Shimon Sakaguchi from Osaka University, Professor Calliope Dendrou from the Kennedy Institute will work on a major research programme to transform the treatment of autoimmune diseases by halting chronic inflammation at its source.
A new partnership between Alice\u2019s Arc, the Centre for Immuno-Oncology in the Nuffield Department of Medicine and the Sir William Dunn School of Pathology will pioneer the development of a bespoke mRNA vaccine to improve treatment outcomes for children with rhabdomyosarcoma, a rare and aggressive form of soft tissue cancer.
A new study, led by researchers at the CAMS Oxford Institute in the Nuffield Department of Medicine and TIDU in the MRC Weatherall Institute of Molecular Medicine, has found that dominant T cell responses years after infection are associated with mild COVID-19 disease, and likely play important protective roles to following viral infections.
Two new papers from University of Oxford scientists have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
Hashem Koohy, Associate Professor of Systems Immunology, has been awarded funding from Wellcome to develop computational strategies to decipher the underlying rules of adaptive T cell immunity.
Oxford scientists build a connected, \u2018multi-organoid\u2019 platform that recreates immune recruitment to the heart, opening new avenues to probe disease and test therapies.
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for infants and children with high-risk leukaemia.
![\"Researcher](\"https://www.immunology.ox.ac.uk/news/oxford-and-gsk-launch-experimental-medicine-collaboration-1/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n